Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 806-815

  Jaeger, Jochen ^a   Koczan, Dirk ^b   Thiesen, Hans Juergen ^b   Ibrahim, Saleh M ^b   Gross, Gerd ^b   Spang, Rainer ^a   Kunz, Manfred ^b  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CELL CYCLE PROTEIN 6; CHEMOKINE CCL27; CONNEXIN 43; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; CYCLIN DEPENDENT KINASE ACTIVATING KINASE 1; DESMOCOLLIN; DESMOCOLLIN 1; DESMOCOLLIN 3; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; KINESIN; OLIGONUCLEOTIDE; OSTEOPONTIN; PROTEIN BCL 2; SEPTIN; SEPTIN 6; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CELL ADHESION; CELL COMMUNICATION; CELL CYCLE REGULATION; CELL SPECIFICITY; CLINICAL ARTICLE; DISEASE COURSE; DOWN REGULATION; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MELANOMA; MELANOMA CELL; METASTASIS; MICROARRAY ANALYSIS; MITOSIS; PATHOGENESIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

CELL ADHESION; CELL COMMUNICATION; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MELANOMA; MUTATION; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES;

EID: 33847397814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1820     Document Type: Article

References (51)

1. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
3. Chapman PB, Einhorn LH, Meyers M, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
4. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
5. Thompson J, Menzies S, Shaw H, Scolyer R, Kefford R. Cutaneous melanoma. Lancet 2005;365:2004-5.
6. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000;1:48-56.
7. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002;20:1932-41.
8. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat Rev Cancer 2003;3:869-76.
9. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
10. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
11. Crnogorac-Jurcevic T, Efthimiou E, NielsenT, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21:4587-94.
12. Zou TT, Selaru FM, Xu Y, et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002;21:4855-62.
13. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
14. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
15. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-5.
16. Bittner M, Meltzer P, ChenY, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
17. Winnipenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-82.
18. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005;102:6092-7.
19. Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481-3.
20. Westphal JR, van't Hullenaar RG, van der Laak JA. et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 1997;76:561-70.
21. Huber W, von Heydebreck A, Sültmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002;18:S96-104.
22. Irizarry R, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
23. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
24. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-5.
25. Cortes C, Vapink V. Support vector networks. Machine Learning 1995;20:273-97.
26. Brown MPS, Groundy WN, Lin D, et al. Knowledge based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A 2000;97:262-7.
27. Ruschhaupt M, Huber W, Poustka A, Mansmann U. A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol 2004;3:article 37.
28. von Heydebreck A, Huber W, Poustka A, Vingron M. Identifying splits with clear separation: a new class discovery method for gene expression data. Bioinformatics 2001;17:8107-14.
29. Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001;13:117-23.
30. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002;20:2530-6.
31. Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005;141:745-50.
32. Büttner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005;103:616-24.
33. Büttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75:2499-506.
34. Meyer D, Leisch F, Hornik K. Benchmarking support vector machines. Neurocomputing 2003;55:169-86.
35. Petersen BO, Lukas J, Sorensen CS, Bartek J, Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J 1999;18:396-410.
36. Fujita M, Yamada C, Goto H, et al. Cell cycle regulation of human CDC6 protein. Intracellular localization, interaction with the human mcm complex, and CDC2 kinase-mediated hyperphosphorylation. J Biol Chem 1999;274:25927-32.
37. Hansel DE, Dhara S, Huang RC, et al. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol 2005;29:390-9.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
39. Weber BL. Cancer genomics. Cancer Cell 2002;1:37-47.
40. Chin L. Modeling malignant melanoma in mice: pathogenesis and maintenance. Oncogene 1999;18:5304-10.
41. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559-70.
42. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003;22:3092-8.
43. Yan Z, DeGregori J, Shohet R, et al. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci U S A 1998;95:3603-8.
44. Murphy N, Ring M, Heffron CC, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005;58:525-34.
45. Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 2004;16:670-8.
46. Laoukili J, Kooistra MR, Bras A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-36.
47. Clark GM, Allred DC, Hilsenbeck SG, et al. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res 1997;57:5505-8.
48. Haass NK, Smalley KSM, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005;18:150-9.
49. Hsu MY, Shih DT, Meier FE, et al. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998;153:1435-42.
50. Trisciuoglio D, Desideri M, Ciuffreda L, et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005;205:414-21.
51. Lomuto M, Calabrese P, Giuliani A. Prognostic signs in melanoma: state of the art. J Eur Acad Dermatol Venereol 2004;18:291-300.